Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish

Biogen's stock fell over 10% after its diranersen Alzheimer's drug missed the primary endpoint in the Phase 2 CELIA trial on May 14. However, the drug showed meaningful reductions in tau pathology and signs of slower clinical decline. Despite the setback, analysts remain bullish with a consensus price target of $215.62, citing the company's decision to advance the drug as a vote of confidence. Biogen's base business is supported by strong Leqembi sales growth (74% YoY to $168M) and the planned Apellis acquisition.

05/22/2026, 8:01 AM • Investing

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.

05/21/2026, 6:00 PM • GlobeNewswire

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), an investigational LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The drug did not slow disease progression compared to placebo. Both companies will discontinue development of BIIB122 in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers with data expected in H1 2027.

05/21/2026, 6:00 PM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

Dow Jones Rally Looks Fragile With Inflation Data Running Hot

The Dow Jones climbed back above 50,000 driven by Cisco's strong earnings beat and guidance raise, while Nvidia gained on news of Chinese H200 chip approvals. However, the rally appears fragile as inflation data runs hot with import prices spiking 1.9% and energy costs surging, offsetting positive consumer resilience metrics. The Trump-Xi summit in Beijing provided mild sentiment support but delivered limited concrete deliverables.

05/14/2026, 12:54 PM • Investing

Why Is Biogen Stock Falling Thursday?

Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.

05/14/2026, 11:57 AM • Benzinga

Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals for $41 per share plus contingent value rights. The deal adds two commercialized products—EMPAVELI and SYFOVRE—which generated $689 million in net product revenue in 2025. The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and significantly boost the company's growth outlook, particularly in nephrology.

05/14/2026, 8:35 AM • Benzinga

Lecanemab Injection Market Report 2026: Increasing Adoption of Monoclonal Antibody Therapies and Rising Focus on Early Alzheimer's Intervention - Global Long-term Forecasts to 2030 and 2035

The lecanemab injection market is experiencing rapid growth, expanding from $2.53 billion in 2025 to $3.07 billion in 2026 at a 21.5% CAGR, with projections reaching $6.63 billion by 2030. Growth is driven by increased early-stage Alzheimer's diagnosis, FDA approvals, Medicare reimbursement expansion, and an aging population. Asia-Pacific is emerging as the fastest-growing region, though tariffs present cost challenges. Key players like Eisai are advancing monoclonal antibody therapies and strategic partnerships to optimize treatment outcomes.

05/11/2026, 10:54 AM • GlobeNewswire

Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy

Biogen shares rose 1.06% to $193.40 despite the FDA extending its review of Leqembi Iqlik by three months to August 24, 2026. The company is also advancing its pipeline through the acquisition of Apellis Pharmaceuticals for $5.6 billion and benefiting from FDA approval of a new high-dose regimen for Spinraza. The stock has gained 63.29% over the past year with positive technical indicators.

05/08/2026, 11:31 AM • Benzinga

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

The FDA has extended the review period by three months for Eisai and Biogen's supplemental application for LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease, with the new action date set for August 24, 2026. The FDA requested additional information but has not raised concerns regarding approvability. The companies remain committed to bringing this advancement to patients.

05/08/2026, 2:30 AM • GlobeNewswire

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

04/29/2026, 1:00 PM • GlobeNewswire

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

Biogen has historically outperformed the market over three decades, but faces current headwinds from biosimilar competition and weak revenue growth. While newer products like Leqembi (Alzheimer's) and high-dose Spinraza show promise with strong growth potential, the company's 2026 guidance projects declining sales. The stock carries heightened risk and is unlikely to deliver strong long-term returns without near-flawless execution.

04/16/2026, 5:30 AM • The Motley Fool

Administrator Loeffler Applauds SBIR-STTR Reauthorization

President Trump signed S. 3971, reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. The legislation includes reforms to strengthen national security, accountability, and innovation. Since 1982, these programs have invested over $81 billion into 34,000+ small businesses and supported major companies including Anduril, Qualcomm, Biogen, Illumina, and iRobot.

04/13/2026, 6:50 PM • GlobeNewswire